ConductScience.org, home

Paper82030

Levamisole in rheumatoid arthritis. A randomised double-blind study comparing two dosage regimens of levamisole with placebo. Multicentre study group.

Lancet, 1978. Cited by 14 papers, by iCite.

Cite this record

ConductScience Library. Levamisole in rheumatoid arthritis. A randomised double-blind study comparing two dosage regimens of levamisole with placebo. Multicentre study group. Papers, record 82030. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/82030

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Levamisole in rheumatoid arthritis. A randomised double-blind study comparing two dosage regimens of levamisole with placebo. Multicentre study group.
PubMed
Journal
Lancet
PubMed
Year
1978
PubMed
Publication types
Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial
PubMed
Citations, by iCite
14
iCite
Relative citation ratio, by iCite
0.8
iCite
Revised in PubMed
2015-06-16
PubMed

Topics15

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Arthritis, RheumatoidMajor topic
LevamisoleMajor topic
Administration, Oral
Adolescent
Adult
Aged
Clinical Trials as Topic
Drug Evaluation
Female
Humans
International Cooperation
Middle Aged
Placebos
Research Design
Time Factors

Source PubMed

Download CSV of topics

Cited by10

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 14 citations.

PMIDTitleJournalYearIn PapersSource
39598415Levamisole Ameliorates Rheumatoid Arthritis by Downregulating the PI3K/Akt Pathway in SD Rats.Pharmaceuticals (Basel)2024https://conductscience.org/library/papers/39598415PubMed
37801318Monotreatment With Conventional Antirheumatic Drugs or Glucocorticoids in Rheumatoid Arthritis: A Network Meta-Analysis.JAMA Netw Open2023https://conductscience.org/library/papers/37801318PubMed
7166176Pharmacokinetics of levamisole in healthy subjects and cancer patients.Eur J Drug Metab Pharmacokinet1982https://conductscience.org/library/papers/7166176PubMed
7144065[Granulocytotoxic antibodies in levamisole-induced agranulocytosis].Klin Wochenschr1982https://conductscience.org/library/papers/7144065PubMed
7009134Antirheumatic drugs: clinical pharmacology and therapeutic use.Drugs1980https://conductscience.org/library/papers/7009134PubMed
6967398An overview of the current status of levamisole in the treatment of rheumatic diseases.Drugs1980https://conductscience.org/library/papers/6967398PubMed
6432411An European open multicentre trial with auranofin in rheumatoid arthritis.Clin Rheumatol1984https://conductscience.org/library/papers/6432411PubMed
3056695The optimum management of arthropathies.Drugs1988https://conductscience.org/library/papers/3056695PubMed
3055380New approaches to the treatment of rheumatoid arthritis.Springer Semin Immunopathol1988https://conductscience.org/library/papers/3055380PubMed
2785367Reflection of disease activity in rheumatoid arthritis by indices of activation of the classical complement pathway.Ann Rheum Dis1989https://conductscience.org/library/papers/2785367PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Authors
  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/82030

GET https://conductscience.org/api/papers/v1/82030/authors